Lorena Bernal-Rubio

Lorena Bernal-Rubio

Auto-generated profile, based on publicly available information

Lorena Bernal-Rubio

Allergy Division, Ramon y Cajal University Hospital, Madrid, Spain

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Closed access
RMRicardo Madrigal-Burgaleta
Ricardo Madrigal-Burgaleta
LBLorena Bernal-Rubio
Lorena Bernal-Rubio
MBMaria Pilar Berges-Gimeno
Maria Pilar Berges-Gimeno
LCLaura Victoria Carpio-Escalona
Laura Victoria Carpio-Escalona
PGPatricia Gehlhaar
Patricia Gehlhaar
EAEmilio Alvarez-Cuesta
Emilio Alvarez-Cuesta

28 July 2020 in Journal of Investigational Allergology and Clinical Immunology
Verified
Journal Article
Closed access
MBMp Berges-Gimeno
Mp Berges-Gimeno
LCLv Carpio-Escalona
Lv Carpio-Escalona
FLF Longo-Muñoz
F Longo-Muñoz
LBL Bernal-Rubio
L Bernal-Rubio
PLP Lopez-Gonzalez
P Lopez-Gonzalez
EAE Alvarez-Cuesta
E Alvarez-Cuesta
Oxaliplatin hypersensitivity reactions may affect prognosis by jeopardizing the timely completion of the scheduled treatment sessions, or by forcing reactive patients into unexpected changes in therapy. Rapid Drug Desensitization (RDD) allows these patients to safely receive their first-choice treatments. However, the possible effects of RDD on the efficacy of oxaliplatin has never been studied. Objective: The objective of this study is to evaluate the effect on survival rates of RDD in oxaliplatin-hypersensitive patients. 7-year retrospective study comparing survival between oxaliplatin-hypersensitive case patients (receiving oxaliplatin by RDD) and non-allergic control patients (receiving standard oxaliplatin infusions). The primary endpoint of this study was Overall Survival (OS) in cases and controls (Kaplan-Meier method with log-rank test comparisons). OS was 23.7 months (95%CI:15.3-30.9) for the 67 cases who underwent 337 RDDs, while for controls (n=143) it was 34.5 months (95%CI:21.7-55.5). There were no significant differences between both groups (HR1.42;95%CI:0.93-2.17;p=0.104). Survival outcomes of oxaliplatin-hypersensitive patients who received oxaliplatin via RDD were not significantly different compared to those of control patients who received oxaliplatin via standard administration. Receiving oxaliplatin by means of RDD might be an effective therapeutic alternative for oxaliplatin-hypersensitive patients.

1 July 2018 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Closed access
PLPaula Lopez-Gonzalez
Paula Lopez-Gonzalez
RMRicardo Madrigal-Burgaleta
Ricardo Madrigal-Burgaleta
LCLaura Victoria Carpio-Escalona
Laura Victoria Carpio-Escalona
LBLorena Bernal-Rubio
Lorena Bernal-Rubio
EGEva Guerra
Eva Guerra
EAEmilio Alvarez-Cuesta
Emilio Alvarez-Cuesta

20 October 2017 in Journal of Investigational Allergology and Clinical Immunology
Verified
Journal Article
Open access
ESEmilio Solano-Solares
Emilio Solano-Solares
RMR Madrigal-Burgaleta
R Madrigal-Burgaleta
LCLv Carpio-Escalona
Lv Carpio-Escalona
LBL Bernal-Rubio
L Bernal-Rubio
MBMp Berges-Gimeno
Mp Berges-Gimeno
EAE Alvarez-Cuesta
E Alvarez-Cuesta
Key words: Chemotherapy, Desensitization, Drug allergy, Mastocytosis, Hypersensitivity